Literature DB >> 7814522

Demonstration of circulating group B streptococcal immune complexes in neonates with meningitis.

J G Vallejo1, C J Baker, M S Edwards.   

Abstract

Group B streptococci are the major cause of sepsis and fatal shock in neonates in the United States. Although a number of clinical features have been associated with enhanced severity of disease, the role of soluble immune complex formation in group B streptococcal infection has not been evaluated. We determined the frequency with which circulating immune complexes occurred in 16 infants with nonfatal type III, group B streptococcal meningitis, using an immunoglobulin-specific C1q enzyme immunoassay. Ten healthy, age-matched infants served as a control group. Elevated levels of immunoglobulin M (IgM)-containing immune complexes were present in the sera of four (25%) patients with group B streptococcal meningitis. Group B antigen was detected in precipitated IgM immune complexes from each of these four infants by competitive enzyme-linked immunosorbent assay. In addition, IgG-containing immune complexes were present in 56% of sick and 60% of control infants. Group B antigen was demonstrated in the serum of a sick neonate containing only IgG immune complexes but not in controls. Our findings indicate that a subset of infants with type III, group B streptococcal meningitis develop IgM immune complexes containing group B-specific antigen, and these may persist for up to 3 months in some patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814522      PMCID: PMC263938          DOI: 10.1128/jcm.32.9.2041-2045.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.

Authors:  H R Hill; L A Gonzales; W A Knappe; G W Fischer; D K Kelsey; H V Raff
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

2.  Patterns of immune response among survivors of group B streptococcal meningitis.

Authors:  M S Edwards; M A Hall; M A Rench; C J Baker
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

3.  Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review.

Authors:  G W Fischer; L E Weisman; V G Hemming
Journal:  Clin Immunol Immunopathol       Date:  1992-01

4.  Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease.

Authors:  H R Hill; D K Kelsey; L A Gonzales; H V Raff
Journal:  Clin Immunol Immunopathol       Date:  1992-01

Review 5.  The role of immune complexes in the pathogenesis of bacterial infections.

Authors:  N Høiby; G Döring; P O Schiøtz
Journal:  Annu Rev Microbiol       Date:  1986       Impact factor: 15.500

6.  Correlation of clinical and pathologic findings in early onset neonatal group B streptococcal infection with disease severity and prediction of outcome.

Authors:  N R Payne; B A Burke; D L Day; P D Christenson; T R Thompson; P Ferrieri
Journal:  Pediatr Infect Dis J       Date:  1988-12       Impact factor: 2.129

7.  Metabolic and hematologic effects and immune complex formation related to pertussis immunization.

Authors:  C M Mink; M Uhari; D A Blumberg; M Knip; K Lewis; P D Christenson; M Toyoda; S C Jordan; S R Levin; J D Cherry
Journal:  Pediatr Res       Date:  1990-04       Impact factor: 3.756

8.  Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia.

Authors:  M A Mellencamp; L C Preheim; T L McDonald
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

9.  Structure of the complex group-specific polysaccharide of group B Streptococcus.

Authors:  F Michon; E Katzenellenbogen; D L Kasper; H J Jennings
Journal:  Biochemistry       Date:  1987-01-27       Impact factor: 3.162

10.  Antigen detection in the diagnosis and in the prognostic assessment of bacterial pneumonias.

Authors:  M W Rytel; L C Preheim
Journal:  Diagn Microbiol Infect Dis       Date:  1986-03       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.